经排除原发性高血压、心功能不全的变异型心绞痛患者65例,分为尼索地平治疗组(治疗组)34例和地尔硫革对照组(对照组)31例。治疗组男20例,女14例,年龄(61±4)岁;对照组男17例,女14例,年龄(60±6) 岁。两组均予卧床休息,吸氧、抗凝、硝酸酯类药物等常规治疗,入院第4日起,治疗组予尼索地平5 mg口服,每日2次,对照组予地尔硫革30 mg口服,每日3次,均连服10日。 Sixty-five patients with variant angina pectoris who were excluded from essential hypertension and cardiac insufficiency were divided into nisoldipine treatment group (treatment group), 34 cases, and diltiazem control group (control group), 31 cases. The treatment group, 20 males and 14 females, aged (61 ± 4) years; control group, 17 males and 14 females, aged (60 ± 6) years. Both groups were given bed rest, oxygen inhalation, anticoagulation, nitrates and other conventional treatment, admission to the 4th day, the treatment group to nisoldipine 5 mg orally, twice daily, the control group to diltiazem 30 mg orally, 3 times a day, even served on the 10th.